Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allosamidin is a small molecule natural product and a potent inhibitor of family 18 chitinases, originally isolated as a secondary metabolite from Streptomyces species. It exhibits strong inhibitory activity against chitinases from various sources, including fungi such as Candida albicans and Coccidioides immitis, with nanomolar potency. The compound acts as a competitive inhibitor by binding to the active site of chitinase enzymes, interfering with their ability to hydrolyze chitin. Allosamidin has been explored for its potential use as an antifungal agent due to its inhibition of fungal chitinases and has also been investigated for possible applications in asthma therapy and as a pesticide. Its mechanism involves direct interaction with catalytic residues in the enzyme active site, stabilizing an inactive conformation[2][3][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allosamidin.